2020 ESC Guidelines on Adult Congenital Heart Disease

EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

IMPACT-Afib Implementation of Stroke Prevention in Atrial Fibrillation

Tackling cardiovascular diseases with a new generation of polypills

ESC Gold Medal 2020 Winner: Kari Stefansson

ESC Gold Medal 2020 Winner: Stefanie Dimmeler

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19

2021 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease

LoDoCo2 Low-Dose Colchicine in Coronary Disease

HOME-PE - Hospitalisation or Outpatient Management of PE Patients - HESTIA vs. Simplified PESI

ESC 2020: Best clinical cases - Awards session

Persistence and cardiovascular outcomes with ramipril, atorvastatin, ASA as a single pill compared to the multi pill combination. A subanalysis of the START study, a claims data analysis

PARALLAX: Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF

Time to reduce the implementation gaps-the role of PCSK9i in routine practice

BPLTTC - Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure